Meta-analysis of a possible signal of increased mortality associated with cefepime use

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages 1350-1351

  Leibovici, Leonard ^a   Yahav, Dafna ^a   Paul, Mical ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; CEFEPIME;

CLINICAL TRIAL; FUNDING; HUMAN; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 78649878181     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657247     Document Type: Letter

References (10)

1. Leibovici L, Yahav D, Paul M. Excess mortality related to cefepime. Lancet Infect Dis 2010; 10:293-294.
2. Kim PW, Wu YT, Cooper C. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51:381-389.
3. Food and Drug Administration. Clinical review, NDA 50-679, cefepime. http://www.fda .gov/downloads/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProvid ers/ DrugSafetyInformationforHeathcareProfes sionals/UCM167313.pdf. Accessed 22 July 2010.
4. Food and Drug Administration. Statistical review and evaluation, NDA 50-679, cefepime hydrochloride. http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyIn formationforPatientsandProviders/ DrugSafety InformationforHeathcareProfessionals/UCM 167309.pdf. Accessed 22 July 2010.
5. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338-348. (Pubitemid 46591956)
6. Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010; 54(10): 4360-4367.
7. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14(4):R126.
8. Chapuis TM, Giannoni E, Majcherczyk PA, et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010; 14(2):R51.
9. Lichaa H, Rachoin JS, Cerceo E, Rajput V, Surkis W. Cefepime: an underrecognized cause of nonconvulsive status epilepticus. J Hosp Med 2010; 5:E18-E19.
10. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-1116.